1. Home
  2. RNTX vs BGSF Comparison

RNTX vs BGSF Comparison

Compare RNTX & BGSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNTX
  • BGSF
  • Stock Information
  • Founded
  • RNTX 2001
  • BGSF 2007
  • Country
  • RNTX United States
  • BGSF United States
  • Employees
  • RNTX N/A
  • BGSF N/A
  • Industry
  • RNTX Biotechnology: Pharmaceutical Preparations
  • BGSF Professional Services
  • Sector
  • RNTX Health Care
  • BGSF Consumer Discretionary
  • Exchange
  • RNTX Nasdaq
  • BGSF Nasdaq
  • Market Cap
  • RNTX 40.3M
  • BGSF 47.7M
  • IPO Year
  • RNTX N/A
  • BGSF N/A
  • Fundamental
  • Price
  • RNTX $1.16
  • BGSF $6.77
  • Analyst Decision
  • RNTX
  • BGSF Strong Buy
  • Analyst Count
  • RNTX 0
  • BGSF 1
  • Target Price
  • RNTX N/A
  • BGSF $9.00
  • AVG Volume (30 Days)
  • RNTX 56.1K
  • BGSF 44.0K
  • Earning Date
  • RNTX 08-13-2025
  • BGSF 08-06-2025
  • Dividend Yield
  • RNTX N/A
  • BGSF N/A
  • EPS Growth
  • RNTX N/A
  • BGSF N/A
  • EPS
  • RNTX N/A
  • BGSF N/A
  • Revenue
  • RNTX N/A
  • BGSF $266,968,000.00
  • Revenue This Year
  • RNTX N/A
  • BGSF N/A
  • Revenue Next Year
  • RNTX N/A
  • BGSF N/A
  • P/E Ratio
  • RNTX N/A
  • BGSF N/A
  • Revenue Growth
  • RNTX N/A
  • BGSF N/A
  • 52 Week Low
  • RNTX $1.04
  • BGSF $2.91
  • 52 Week High
  • RNTX $4.40
  • BGSF $9.06
  • Technical
  • Relative Strength Index (RSI)
  • RNTX N/A
  • BGSF 58.67
  • Support Level
  • RNTX N/A
  • BGSF $6.00
  • Resistance Level
  • RNTX N/A
  • BGSF $7.17
  • Average True Range (ATR)
  • RNTX 0.00
  • BGSF 0.40
  • MACD
  • RNTX 0.00
  • BGSF -0.03
  • Stochastic Oscillator
  • RNTX 0.00
  • BGSF 65.81

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.

Share on Social Networks: